ESMO 2018 | Rob Jones reviews: practice-affirming and -changing data in prostate cancer
From the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, Robert Jones, MD, PhD, of the University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK, presents and analyzes interesting results from clinical trials for prostate cancer. Prof. Jones reflects on the STAMPEDE (NCT00268476) and LATITUTDE (NCT01715285) trials, investigating the role of abiraterone in prostate cancer. He also discusses another STAMPEDE analysis, of patients with metastatic disease who are receiving ADT for the first time, investigating whether radiotherapy to the primary tumor will improve survival time.
Get great new content delivered to your inboxSign up